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Background: There's a large clinical need for novel vascular grafts. Tissue engineered blood vessels
(TEBVs) have great potential to improve the outcome of vascular grafting procedures. Here, we present a
novel approach to generate autologous TEBV in vivo. Polymer rods were engineered and implanted,
evoking an inflammatory response that culminates in encapsulation by a fibrocellular capsule. We hy-
pothesized that, after extrusion of the rod, the fibrocellular capsule differentiates into an adequate
vascular conduit once grafted into the vasculature.
Methods and results: Rods were implanted subcutaneously in pigs. After 4 weeks, rods with tissue
capsules grown around it were harvested. Tissue capsules were grafted bilaterally as carotid artery
interposition. One and 4-week patency were evaluated by angiography whereupon pigs were sacrificed.
Tissue capsules before and after grafting were evaluated on tissue remodeling using immunohisto-
chemistry, RNA profiling and mechanical testing. Rods were encapsulated by thick, well-vascularized
tissue capsules, composed of circumferentially aligned fibroblasts, collagen and few leukocytes, with
adequate mechanical strength. Patency was 100% after 1 week and 87.5% after 4 weeks. After grafting,
tissue capsules remodeled towards a vascular phenotype. Gene profiles of TEBVs gained more similarity
with carotid artery. Wall thickness and aSMA-positive area significantly increased. Interestingly, a sub-
stantial portion of (myo)fibroblasts present before grafting expressed smooth muscle cell markers. While
leukocytes were hardly present anymore, the lumen was largely covered with endothelial cells. Burst
pressure remained stable after grafting.
Conclusions: Autologous TEBVs were created in vivo with sufficient mechanical strength enabling
vascular grafting. Grafts differentiated towards a vascular phenotype upon grafting.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Small caliber vascular graft failure is still a frequent complica-
tion in vascular surgery, involving substantial morbidity [1] andical Center, Department of
he Netherlands.
.
health care costs [2]. Autologous vessels are used as golden stan-
dard as they show superior patency when compared with synthetic
grafts in various vascular settings, such as peripheral bypass grafts
[3,4] and arteriovenous grafts for hemodialysis access [5,6]. The
inferiority of synthetic grafts is attributed to the lack of compliance,
thrombogenic surface and continuous presence of synthetic ma-
terial in the vasculature [1,7]. Unfortunately, native vessels are
frequently unavailable or unsuitable for surgical procedures [8,9]
T.C. Rothuizen et al. / Biomaterials 75 (2016) 82e90 83due to pre-existent vascular disease [10e12].
Tailor-made tissue engineered blood vessels (TEBVs) could offer
a better alternative for prosthetic grafts. Most vascular tissue en-
gineering approaches aim to develop off-the-shelf vascular grafts
consisting of extracellular matrix (ECM) that in some cases is pre-
seeded with vascular cells before implantation into the vascula-
ture [13e15]. Recently, we described a method for in situ vascular
tissue engineering that allowed us to generate autologous TEBVs
in vivo in only a few weeks [16,17]. This approach utilizes the
foreign body response (FBR) directed to a subcutaneously implan-
ted polymer rod that culminates into the formation of a fibrocel-
lular tissue capsule. Upon extrusion of the rod several weeks after
implantation, the remaining tissue capsule is grafted into the
vasculature whereupon it could differentiate towards a vascular
phenotype. Indeed, flow and wall tension can enhance matrix
synthesis [18,19] and vessel wall thickening [20], (myo)fibroblast to
vascular smooth muscle cell (VSMC) differentiation [21] and
luminal caliber remodeling to adapt the tissue to the present he-
modynamic situation [20,22,23].
In previous in vitro [16] and in vivo [17] studies, we showed that
the implant material's surface largely dictates the morphology and
composition of the formed tissue. Based on these studies, we
selected the optimal polymer compound and surface to generate a
tissue capsule that forms a suitable basis for a TEBV. Our previous
in vivo rat study revealed that the tissue capsules generated with
this method were well vascularized capsules largely composed of
circumferentially aligned collagen and (myo)fibroblasts. Here, we
describe the development of TEBVs in a porcine model and the
remodeling towards a vascular phenotype upon grafting as autol-
ogous carotid interposition graft.
2. Materials and methods
2.1. Study design
Experiments were approved by the Animal Care Committee of
the University Medical Center Utrecht and performed according to
Dutch legislation, using 4 female Landrace pigs weighing approxi-
mately 40 kg. Cylindrical shaped polymer rods as described below
more detailed were implanted subcutaneously. Four weeks later,
rods with tissue capsules grown around it were harvested. Per pig,
2 tissue capsules were used as autologous vascular graft for bilat-
eral carotid artery interposition. Thus, in total 8 tissue capsules
were bilaterally grafted. Remaining tissue capsules were used for
histology, RNA isolation and mechanical assessment. A biodegrad-
able, elastic sheet was wrapped around the vascular graft and
anastomosis for temporal external support during the first period
of tissue capsule remodeling after exposure to flow. As standard
antiplatelet therapy [24], pigs received 80 mg/d acetylsalicylic acid
starting 6 days before vascular surgery until termination and
225 mg clopidogrel one day before vascular surgery, continued at
75 mg/d until termination. Patency was assessed by angiography 1
week and 4 weeks after vascular surgery whereupon pigs were
sacrificed and tissue capsules were harvested. Tissue capsules
before vascular grafting were compared to tissue capsules 4 weeks
after vascular grafting to evaluate tissue remodeling after exposure
to flow and strain.
2.2. Implant material
Solid cylindrical rods of 8 cm length and 4.2 mm diameter were
fabricated using a stainless steel compression molding device. Rods
were composed of the co-polymer poly(ethylene oxide
terephthalate)epoly(butylene terephthalate) (PEOT/PBT, Poly-
vation, The Netherlands), with a PEOT/PBT weight percentage of55/45 and 300 g/mol molecular weight of the initial polyethylene
glycol used for the copolymer reaction. The implant surface was
modified by etching with chloroform as previously described
[16,17]. Surface topography of all modified rodswas evaluated using
SEM. In addition, surface roughness (Rq) of unmodified and chlo-
roform etched rods wasmeasured with AFM, using Tapping 1Mode
(PicoScan Controller 2500, Molecular Imaging, USA) with a sharp
TESP cantilever: 42 N/m, 320 kHz, 2e5 nm ROC, No Coatings
(Bruker AFM Probes). For unmodified and modified rods, 4 rods
were analyzed, using 4 spots of 25 mm2 per rod. Roughness was
assessed with Scanning Probe Image Processor, SPIPTM, version
4.2.2.0 software.
External electrospun sheets were composed of poly-ε-capro-
lactone (PCL) (Purac Biomaterials, The Netherlands). Rods and
sheets were sterilized using gamma-radiation of >25 kGy (Synergy
Health, The Netherlands). The effect of gamma-radiation on the
surface was evaluated using SEM.
2.3. Surgical procedures
Per pig, 6 rods were implanted subcutaneously in the abdominal
area. A small incision was made and a pocket of 8 cm length was
bluntly prepared. Rods were inserted in the pocket and attached to
the abdominal wall using 4-0 prolene sutures. The skin was closed
intracutaneously. Four weeks after insertion of the rods, tissue
capsules with the rods were harvested. In short, a longitudinal
incision lateral to the rod was made and the tissue capsule was
gently removed from the surrounding tissue. After harvesting, rods
could easily be extruded from the tissue capsule. Subsequently,
tissue capsules were bilaterally inserted as autologous carotid ar-
tery interposition. Briefly, a midline incision in the neck was made
and the carotid artery was dissected. After infusion of 100 IU/kg
heparin intravenously, the carotid artery was clamped proximally
and distally of the anastomosis site. A 3 cm segment of the carotid
artery was excised and replaced by 4 cm tissue capsule using 2 end-
to-end anastomoses. Subsequently, the flow was measured using a
perivascular flow probe. Next, the external sheet was wrapped
around the tissue capsule and covered 1 cm carotid artery adjacent
to each anastomosis. After wrapping around the graft, the 2
neighboring ends of the sheet were interconnected using 6-0 su-
tures as illustrated in Fig. 1D. To assess patency, an angiographywas
performed 1 week after vascular grafting and before termination at
4 weeks after grafting. The excised carotid artery segment was used
for histological assessment and RNA isolation.
2.4. Cannulation of tissue capsule
In each pig, one of two grafts was cannulated with a 16G dialysis
needle. After removal of the needle, the cannulation site was digi-
tally compressed for at least 3 min or until hemostasis was reached.
Time to hemostasis was recorded.
2.5. Tissue capsule analysis
Tissue capsules before and after vascular grafting were pro-
cessed and paraffin-embedded. Serial 5 mm cross-sections of the
middle of the tissue capsules before and after grafting were made
for morphometric and (immuno)histochemical analysis. Moreover,
RNA was isolated from tissue capsules before and after vascular
implantation and from a non-operated carotid artery. RNA was
profiled (AROS, Danmark) using a porcine microarray (Affymetrix,
Germany). A heatmap of all 3 groups was generated. Subsequently,
gene profiles of tissue capsules before grafting were compared to
tissue capsules after grafting. Genes with 8-fold difference and
p  0.0001 were selected. In addition, genes associated with ECM
Fig. 1. Macroscopic pictures of the tissue capsule. A. Polymer rod in situ in the subcutaneous space is completely encapsulated by a fibrocellular tissue capsule. B. After harvesting of
the tissue capsule, the tissue capsule is smoothly extruded from the polymer rod. C. Tissue capsule as carotid artery interposition. D. External sheet is applied around the tissue
capsule and anastomosis. Scale bar represents 2 cm.
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and evaluated in our dataset. For mechanical evaluation, derived
burst pressure was measured on 0.5 cm long tissue capsule seg-
ments before and after grafting. Suture retention strength (SRS)
was measured on 1 cm segments of tissue capsules before grafting
using 6-0 sutures and compared to similar specimens of porcine
jugular veins and carotid arteries. Thirdly, compliance was
measured on a 5 cm segment of tissue capsules before grafting. All
analyses are described more detailed in the Supplementary
Materials & methods section.
2.6. Statistical analysis
Data are presented as mean ± standard error of the mean (SEM).
Data from the histological measurements and burst pressure before
versus after grafting were analyzed with a paired t-test using SPSS.
The other non-paired mechanical test results where tissue capsules
were compared with native vessels were analyzed using a One-way
ANOVAwith Dunett post-hoc test with the tissue capsule values as
reference. For luminal measurements where all groups were
compared with each other, a One-way ANOVA test with a Tukey




The smoothness of the unmodified rods was confirmed with
SEM (Suppl. Fig. 1A). The roughness of the unmodified rods (Rq)
was 68.68 ± 20.26 nmwhereas this was 294.80 ± 25.58 nm for the
chloroform etched rods. Chloroform etching resulted in all cases in
homogenously spread porous structures of 0.5e2.5 mm in diameter
(Suppl. Fig. 1B). SEM-images of the PCL sheet confirmed the spec-
ified fiber dimensions and porosity (Suppl. Fig. 1C). Gamma-
irradiation did not affect the surface topography of the rods and
sheets (data not shown). The Young's modulus of the PCL sheet
after gamma-radiation was 9.0 ± 0.2 MPa.
3.2. Surgical procedure
Four weeks after subcutaneous implantation, a thick walled
tissue capsule was formed around the rods (Fig.1A). Tissue capsules
could easily be harvested and subsequently smoothly extruded
from the rod (Fig. 1B). All carotid artery interpositions went suc-
cessful (Fig. 1CeD). One-week patency after vascular surgery was
100% (8/8) and 4-week patency was 87.5% (7/8). The initial tissue
capsule diameter matched with the carotid artery diameter
(Fig. 2C). One and 4 weeks after vascular surgery, some peri-
anastomotic stenosis was observed on angiography (Fig. 2AeB)and confirmed by histology (Fig. 2DeE) and luminal measurements
of the anastomosis (Fig. 2C). Subsequent to the anastomotic luminal
narrowing, the luminal diameter of the tissue capsule increased
throughout the graft reaching amaximum at themiddle of the graft
(Fig. 2C,F). The luminal diameter of the grafts increased with
maintenance of adequate all wall thickness, thus suggesting out-
ward remodeling in response to arterial blood flow and pressure.
3.3. Tissue capsule formation
Before vascular grafting, tissue capsules were mainly composed
of ECM (Fig. 3BeE) and fibroblasts (Fig. 4E). Althoughwall thickness
varied within each tissue capsule, no thin spots were observed. The
ECM was composed of collagen I and III (Fig. 3BeC) and glycos-
aminoglycans (GAGs) (Fig. 3D). In contrast to the abundance of
collagen, elastin was scarce (Fig. 3E). There was no calcification
(Fig. 3F).
Tissue capsules were well-vascularized as illustrated by the von
Willebrand factor staining (Suppl. Fig. 2B), but as expected lacked
an endothelial luminal lining (Fig. 5A). Although some cells in the
lumen were lectinþ, they lacked the typical endothelial pattern as
observed in native arteries (Fig. 5D). The first cell layers in the
luminal area that approximated the synthetic rod were largely
occupied by leukocytes (Fig. 4B), partly macrophages negative for
M2-macrophage marker CD163 (Fig. 4CeD; Fig. 6). Hardly any
foreign-body giant cells were observed. Apart from the luminal
area, the majority of the tissue capsule was composed of
vimentinþ, a-SMA- and cytokeratin-fibroblasts (Fig. 4EeF; Fig. 6).
In addition, some myofibroblasts (Fig. 4F; Fig. 6) were present, and
very little cells expressed VSMCs markers; these cells were mainly
part of the tissue capsule's microvasculature (Fig. 4G; Fig. 6).
3.4. Tissue capsule remodeling after vascular grafting
After grafting, tissue capsules largely remodeled into thick
walled, homogeneous grafts. Paralleled by the increase in luminal
diameter (Fig. 2C), the wall area and thickness increased as indi-
cated by the collagen measurements (Fig. 6). The ECM remained
largely composed of densely packed and circumferentially aligned
collagen I and III (Fig. 3HeI) and GAGs (Fig. 3J). Elastin was scarcely
present, only locally around the sheet at the “adventitial” site of the
tissue capsule (Fig. 3K).
In contrast to the cellular composition before grafting (Fig. 4),
tissue capsules after grafting were mainly composed of a-SMAþ
and desminþ VSMC-like cells (Fig. 6; Fig. 7EeG). Histo-
morphometry confirmed a 27-fold increase in desminþ area and an
almost 10-fold increase in percentage desmin-positivity of the total
wall (Fig. 6). These VSMC-like cells were largely circumferentially
aligned and in a non-proliferative state (Fig. 7H). The remaining
cells in the tissue capsule were a-SMAþ, desmin-myofibroblasts
Fig. 2. Angiography of the carotid interposition after 1 (A) and 4 (B) weeks, showing a relative stenosis at the anastomotic area and some dilation of the tissue capsule. C.
Quantification of the luminal diameter in mm indicates that the initial diameter of the tissue capsule fits well with the carotid artery. Four weeks after grafting the luminal diameter
is declined at the anastomotic area but expands towards the middle of the graft. DeF: Haematoxylin phloxine saffron (HPS) stained cross-sections of D. carotid artery, E. anastomotic
part of the tissue capsule and F. midgraft section of the tissue capsule. The stenosis in E is mainly composed of matrix and (myo)fibroblasts. Scale bar represents 2000 mm.
T.C. Rothuizen et al. / Biomaterials 75 (2016) 82e90 85(Fig. 6; Fig. 7FeG). The leukocytes observed at the lumen before
grafting (Fig. 4B) were barely present 4 weeks after grafting (Fig. 6;
Fig. 7B). Instead, the lumen was largely covered with a confluent
single endothelial layer demonstrated by a lectin stain exhibiting
similar staining patterns as endothelial cells in a native artery
(Fig. 5BeD).
The vascularization of the tissue capsule before grafting was
interrupted during its harvesting. This could potentially affect the
oxygenation of the tissue after grafting. However, 4 weeks after
vascular grafting an extensive capillary network was present,
especially in the outer layer of the capsule and in the external sheet
(Suppl. Fig. 2C). Considering the above, these are likely in part
newly formed capillaries. HIF1a and TUNEL staining confirmed no
large areas of hypoxia or necrosis present (Suppl. Fig. 3).
Throughout the tissue capsules, only little TUNELþ spots were
observed (Suppl. Fig. 3) which co-localized with the HIF1a staining.
In addition, few Ki67þ proliferating cells were present in the tissue
capsule 4 weeks after grafting (Fig. 7H).
3.5. mRNA profiles of tissue capsules
In total, 25,740 genes were profiled using RNA from the tissue
capsules before and after grafting and from a non-operated carotidFig. 3. Cross-sections of the matrix composition of the tissue capsule before grafting (uppe
native carotid artery (lower row, MeR). The lower row (MeR) can be used to compare the ti
(HPS) staining, brightfield image of picrosirius red staining for collagen, polarized light image
elastin and alizarin red staining for calcification. The matrix of the tissue capsules is largely
native vessel (Q), little elastin is present (E, K). Similar to a native vessel (R), no calcifications
200 mm. (For interpretation of the references to color in this figure legend, the reader is reartery. Genetic profiles of the tissue capsule before grafting differed
substantially from a porcine carotid artery as mRNA levels of 3749
genes were higher and mRNA levels of 3236 genes were lower
expressed in the tissue capsules before grafting. In contrast, 4
weeks after grafting, these differences in genetic profile were
considerably reduced. Compared to a carotid artery, mRNA
expression of 1479 genes was higher and mRNA expression of 1548
genes was lower in the tissue capsules after grafting (Suppl. Fig. 4).
When tissue capsules after interposition were compared to
before grafting, 662 geneswere significantly differentially expressed
(P < 0.05 with >2-fold difference, Suppl. Fig. 4B). Genes that both
displayed 8-fold difference and p  0.0001 were selected
(Suppl. Fig. 4B, black box) and summarized in Suppl. Fig. 4C. In
addition, genes associated with ECM remodeling, endothelial cells
and VSMCs were selected. Differential expression of these genes is
summarized in Suppl. Table 1e3. Whereas endothelial cell genes
were both up and down-regulated (Suppl. Table 1), possibly
reflecting both the luminal endothelialization as well as the turn-
over of capillaries in the “adventitial” side, interestingly all VSMC
genes were uniformly upregulated (Suppl. Table 2). Downregulation
of tissue inhibitors of matrix metalloproteinases (TIMPs) combined
with upregulation of some matrix metalloproteinases (MMPs) may
suggest ECM remodeling (Suppl. Table 3).r row, AeF), tissue capsule four weeks after vascular grafting (middle row, GeL) and a
ssue capsule to a native blood vessel. From left to right: Haematoxylin phloxine saffron
of picrosirius red staining, alcian blue staining for GAGs, Weighert's elastin staining for
composed of collagen type I and III (BeC, HeI, NeO) and GAGs (D, J, P). In contrast to a
in the tissue capsules before (F) or after grafting (L) were observed. Scale bar represents
ferred to the web version of this article.)
Fig. 4. Cross-sections of the cellular composition of the tissue capsule before vascular grafting. A. Haematoxylin phloxine saffron (HPS) overview, B. CD45, C. anti-macrophage, D.
CD163, E. vimentin, F. a-SMA, G. desmin and H. Ki67. Tissue capsules were mainly composed of fibroblasts. The luminal area was covered with leukocytes, in part macrophages
negative for M2 marker CD163. Scale bar represents 200 mm.
Fig. 5. Lectin staining of A. tissue capsule before grafting, BeC. tissue capsule after grafting, D. carotid artery. Although some cells in the tissue capsule before grafting (A) stain
positively, this is not a typical endothelial staining pattern as observed in a native artery (D) and are more likely leukocytes that can also be lectin positive. In contrast, four weeks
after vascular grafting, a confluent lectin positive line (B-c) typical for endothelial cells (D) was observed, suggesting endothelialization of the tissue capsule. Scale bar A, CeD
represents 20 mm; scale bar B represents 200 mm.
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The SRS, burst pressure and compliance of the tissue capsules
before grafting as well as burst pressure 4 weeks after vascular
grafting are summarized in Table 1. While the SRS was comparable
to native vessels, the burst pressure was lower than in native veins
and arteries. However, all tissue capsules had burst pressures well
above proposed required values for TEBVs [25] and by far exceedingFig. 6. Quantification of the tissue composition before and after vascular grafting. The total p
vascular grafting of fibroblasts (using a vimentin staining), myofibroblasts (using an a-SMA
macrophages (using a macrophage staining) as well as the total amount of collagen (using
vascular grafting, tissue capsules were mainly composed of fibroblasts as indicated by the vi
CD45þ cells; these were partly macrophages as indicated by the percentage of macrophage
content. In addition, the CD45þ leukocytes largely disappeared and more a-SMA and de
*p < 0.05, ***p < 0.001.physiological values. Importantly, burst pressure remained stable 4
weeks after vascular grafting (Table 1). In contrast to the SRS and
burst pressure, compliances values were low.
3.7. Cannulation of tissue engineered blood vessel
Tissue engineered carotid interpositions were cannulated in vivo
with a dialysis needle. Time to hemostasis after digital compressionositive area in mm2 and percentage DAB positivity in the tissue capsule before and after
staining), VSMCs (using a desmin staining), leukocytes (using a CD45 staining), and
a picrosirius red staining) were quantified on brightfield images using ImageJ. Before
mentin quantification. Some leukocytes were present as indicated by the percentage of
s. After vascular grafting, tissue wall thickened as indicated by the increase in collagen
smin positive cells were present compared with before grafting. NS: non significant,
Fig. 7. Cross-sections of the cellular composition of the tissue capsule 4 weeks after vascular grafting. A. Haematoxylin phloxine saffron (HPS) overview, B. CD45, C. anti-
macrophage, D. CD163, E. vimentin, F. a-SMA, G. desmin and H. Ki67. Tissue capsules largely remodeled during vascular grafting. Tissue was mainly composed of non-
proliferative a-SMAþ and desminþ VSMCs. The lack of proliferation suggests a steady state has been reached. The leukocytes present before vascular grafting largely dis-
appeared. * indicates the location of the external sheet. The sheet is resolved due to laboratory processing. Scale bar of A. represents 2000 mm. All other scale bars represent 200 mm.
T.C. Rothuizen et al. / Biomaterials 75 (2016) 82e90 87was in all cases 3 min, comparable to native vessels.
4. Discussion
In the present study, we developed an autologous, completely
biological vascular conduit in only four weeks using the subcu-
taneous space as in vivo bioreactor, with sufficient mechanical
strength to allow safe vascular implantation. During vascular
grafting, this vascular conduit remodeled towards a vascular
phenotype.
4.1. Remodeling of tissue capsule towards a vascular phenotype
Before vascular grafting, tissue capsules were mainly composed
of ECM and fibroblasts. Fibroblasts are plastic cells that if stimu-
lated can excrete and react to growth factors, chemokines and cy-
tokines, differentiate, can acquire a contractile apparatus and play a
key role in matrix synthesis and remodeling [26,27]. Importantly,
flow and cyclic stretch are potent stimuli for ECM synthesis and
remodeling [19,28,29], and even (myo)fibroblast to VSMC differ-
entiation [21]. Indeed, 4 weeks after grafting, the capsule wall
thickened and cell number and amount of ECM increased. This
arterialization process is also observed in venous grafts exposed to
arterial hemodynamic conditions [20,22,29]. In addition, after
vascular grafting collagen fibers in the tissue capsule were more
densely packed and circumferentially aligned, thus increasingly
mimicking the medial layer of a native blood vessel. Probably, the
exposure to arterial hemodynamics promoted further circumfer-
ential alignment of cells and collagen [30].
Remarkably, fibroblasts in the tissue capsule acquiredTable 1
Overview of mechanical test results of tissue capsule before and after grafting as compa
Compliance (%/100 mm Hg)
Carotid artery e
Jugular vein e
Tissue capsule before grafting 7,46 ± 2,61
Tissue capsule after grafting econtractile VSMC characteristics, as indicated by a-SMA and des-
min expression, their non-proliferative state and the uniform
upregulation of contractile VSMC-genes [31]. These VSMC-like cells
were observed throughout the entire 4 cm length of the graft.
Although migration of cells from the adjacent carotid artery cannot
be fully excluded, the presence of these cells at substantial distance
from the anastomosis rather suggests differentiation of fibroblasts
into VSMC-like cells. Indeed, cyclic stretch of fibroblastic cells
present in granulation tissue upregulates the volume fraction of
myofilaments substantially in vitro and in vivo [21]. Underlining the
above, total gene profiles suggested that tissue capsules 4 weeks
after vascular grafting gained more similarity with a carotid artery
in gene profiles as compared to tissue capsules before vascular
grafting.
4.2. Extinction of the inflammatory response after removal of
implant material
The luminal area of tissue capsules at baseline was covered
with leukocytes. These leukocytes were attracted by the presence
of the synthetic rod as part of the FBR [32]. Implantation of syn-
thetic material evokes an inflammatory response dominated by
neutrophils and macrophages [32,33]. This gradually shifts to-
wards a more fibrotic response characterized by (myo)fibroblasts
and ECM deposition [32,34]. The inflammatory lining of the tissue
capsule was in part composed of M1 macrophages, a key effector
cell in the foreign body response [32]. Remarkably, these leuko-
cytes largely disappeared after vascular grafting. This suggests
that removal of the foreign body largely extinguishes the associ-
ated inflammatory response. This observation is in line withred with a native vein and artery.
SRS (N) Burst pressure (mm Hg)
6,08 ± 1,51 10.010,92 ± 1090,09
6,01 ± 1,99 10.686,44 ± 1.992,08
5,81 ± 1,08 3.947,26 ± 576,66
e 5.211,04 ± 358,32
T.C. Rothuizen et al. / Biomaterials 75 (2016) 82e9088previous studies showing resolution of the FBR upon complete
degradation of synthetic implants [35] or successful encapsulation
of a foreign body [32].
4.3. Endothelialization
In contrast to native vessels, the generated tissue capsules did
not have a luminal endothelial lining at time of vascular implan-
tation. The tissue capsules' lumen is rich of collagen and Tissue
Factor, thus intrinsically thrombogenic. Nonetheless, no acute
thrombosis was observed. The occlusion of the non-patent graft in
our study was attributed to peri-anastomotic intimal hyperplasia
rather than primary thrombosis. Although preferable, the absolute
necessity of an endothelial lining in TEBVs prior to vascular im-
plantation in especially larger diameter and high flow situations
remains a matter of debate. For larger diameter, high flow appli-
cations such as hemodialysis vascular access and above the knee
bypass grafts, it has been proposed to use TEBVs without endo-
thelial lining [13]. Conventional ePTFE grafts do not have an
endothelial lining either, yet show little acute thrombosis. Indeed, if
present, thrombosis is mainly secondary to stenotic intimal hy-
perplastic lesions [24]. Possibly, if the flow is high enough, in the
presence of anti-platelet therapy, platelets will not adhere sub-
stantially to the surface. Although most vascular tissue engineering
approaches aim to endothelialize their vascular constructs, some
reports of TEBVs with very little or no initial endothelial coverage
showed excellent long-term patency in small [35] and large [13]
animal models. Currently, large clinical trials with non-
endothelialized blood vessels are being performed with little
thrombosis in the first months of follow-up [14] (clinicaltrials.gov,
NCT01872208 and NCT01744418).
Four weeks after grafting, an endothelial lining was observed
largely throughout the vascular graft. Unfortunately, there are no
porcine antibodies for endothelial markers that exclusively stain
the endothelium on large blood vessels. Indeed, a vWF antibody
only stained the vaso vasorum in porcine native arteries. In our
experience, the commonly used CD31 marker does not cross-react
with porcine endothelium when using immunohistochemistry.
Therefore, lectin was used as alternative marker [36]. However, a-
SMA positive cells and leukocytes can also express lectin [37,38].
Although sufficient a-SMA positive cells were present in the graft,
only a single luminal layer stained lectinþ, in a similar pattern as
endothelial cells of a native artery. In addition, the single luminal
cell layer that stained lectin positive, was negative for other
markers such as a-SMA, CD45 and keratin, thus ruling out many
other potential cell types. Although not irrefutable, in our opinion
the above strongly suggests the presence of an endothelial lining 4
weeks after vascular grafting. In contrast to histology, RNA profiling
results showed a mixed pattern of up and downregulation of
endothelial genes. This may likely reflect the disruption of capil-
laries in the tissue capsule after harvesting from the subcutaneous
space, the newly formed capillaries as well as the luminal lining of
endothelial cells.
4.4. Mechanical properties of TEBV
Tissue capsules showed adequate mechanical strength to
allow safe implantation. SRS was comparable to values of native
arteries and veins, and well above required values [25]. Burst
pressure values were lower than native vessels, but still well
above the required 1600 mm Hg [25], and remained stable after
vascular grafting. The amount and especially the circumferential
alignment of collagen likely contributed to the mechanical
strength [39]. In contrast, compliance was relatively low due to
the little amount of elastin present in the tissue capsule. Indeed,induction of elastogenesis in adult cells is a major challenge in
vascular tissue engineering [40]. Interestingly, flow and cyclic
stretch are potent stimuli for elastogenesis [18,41] for elastogenic
cells such as (myo)fibroblasts and VSMCs [42] present in the
tissue capsule. Longer-term follow-up experiments should reveal
if in time elastogenesis and consequently compliance are
increased.4.5. Intimal hyperplasia
Angiographies at 1 and 4 weeks after vascular grafting showed
some luminal narrowing at the anastomotic site. Although our
engineered grafts lack a well-defined intimal layer, histology
confirmed a local accumulation of matrix, randomly aligned (myo)
fibroblasts and VSMCs, all hallmarks for intimal hyperplasia [43].
However, this did not result in decreased patency. Indeed, we
showed a patency of 87.5% after 4 weeks (7/8). Our end-to-end
anastomotic configuration of the interposition is prone for
luminal inversion of the rims creating a slight surgical stenosis.
Unfortunately, no angiographies were performed directly after
surgery to evaluate the surgical procedure. However, these lesions
were present at the angiography one week after vascular grafting
which suggest a significant contribution of surgically induced tis-
sue injury. In addition, compliance mismatch of the graft with the
carotid artery may contribute to intimal hyperplastic lesions [44].
As end-to-end configurations are less commonly performed in
vascular surgery, future studies focusing on patency instead of
tissue remodeling should use a more clinically relevant vascular
model, such as an end-to-side bypass configuration or arteriove-
nous graft.4.6. Other vascular tissue engineering approaches
Since the first TEBV created by Weinberg and Bell, the vascular
tissue engineering field has rapidly expanded. Currently, a wide
variety of vascular tissue engineering methods are being devel-
oped. Their common aim is to create a completely biological blood
vessel that is rapidly available and cost-effective. Some groups have
already reached clinical implantation. L'Heureux et al. were the first
to generate a clinically applied biological TEBV, without the use of a
synthetic scaffold. Concentric layers of cell sheets were generated
from isolated fibroblasts to create a tubular structure and endo-
thelial cells were seeded in the luminal side. Using this tissue en-
gineering by assembly (TESA) method, TEBVs were created with
sufficient mechanical properties to allow human implantation as
arteriovenous graft [45]. Despite promising primary patency rates
of 60% in 6 months [46], the TEBVs were encumbered with high
production costs and long production time, thus limiting wide
spread clinical use. Therefore, recently these TEBVs were devi-
talized and implanted as acellular arteriovenous graft [14]. In
addition, the Human Acellular Vascular Graft as developed by
Niklason et al. has recently reached clinical implementation. In this
scaffold-based method, allogenic VSMCs were isolated and seeded
on tubular, degradable polyglycolic acid scaffolds in vitro and
cultured in a pulsatile bioreactor system. The scaffold was gradually
replaced by ECM in vitrowhereupon grafts where decellularized to
remove all allogeneic cells. After successful studies in baboons and
dogs [13], these TEBVs were recently evaluated in a clinical trial as
hemodialysis access conduit [47]. Primary patency of these TEBV
was 60% at 6-months, which is comparable to prosthetic arterio-
venous grafts.
In contrast to the methods above, our in situ tissue engineering
method rapidly generates cellular, biological, autologous TEBVs. In
addition, laborious and expensive in vitro steps are circumvented.
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The concept of in vivo vascular tissue engineered has previously
been studied. Sparks pioneered this method in 1969, using a so-
called Sparks mandril [48]. This multi-layered implant device was
typically implanted intramuscularly for several months and
generated autologous tissue capsules with a Dacron mesh incor-
porated in the graft wall [48,49]. Although initial results as vascular
graft in canine and human studies were encouraging [49,50], these
grafts largely failed due to thrombosis and aneurysm formation
[51e53]. Likely, these dismal results can be attributed to the
random selection of biomaterials, the continuous presence of
synthetic material and the lengthy implantation period of the
implant device comprising several months, yielding tissue capsules
with low cellularity. Indeed, the FBR is dynamic, starting with an
inflammatory phase that in weeks shifts to a fibrotic response and
after months, a relatively acellular collagenous tissue capsule re-
mains [32]. It was concluded not to use this method anymore until
more was known about the FBR [54]. Many of the questions
regarding the mechanisms of the FBR, limiting the usage of this
method, are presently answered, enabling optimization of this
ingenious method. Recently we developed and tested a set of
different physical, chemical and biological surface modifications on
their ability to actively steer the tissue capsule formation showing
distinct differences in tissue composition, arrangement and cell
distribution per implant material [17]. The best functioning surface
was used in the present study. Thus, in contrast to Sparks' studies,
here we used preselected material specifically designed to evoke a
controlled inflammatory response thus enabling tailored tissue
formation. In addition, implant period was shortened, as implant
period is crucial to the cellularity and composition of the FBR and
the subcutaneous space was used as implant site rather than the
muscle.
A similar in vivo approach was described using the peritoneal
cavity [55]. Importantly, not all rods implanted in the peritoneal
cavity were encapsulated by a tissue capsule [55,56], making it
necessary to implant multiple rods. In addition, using the perito-
neal cavity as bioreactor is much more invasive with risk of adhe-
sions, limiting clinical application. Instead, the subcutis is easily
accessible.
4.8. Study limitations
Our study has some potential limitations. Importantly, this is a
short-term follow-up study especially valuable to describe the
remodeling process after vascular grafting. Although there are
promising short term results, long term follow-up studies are
required to evaluate patency and complications typically associated
with longer term follow-up, such as aneurysm formation.
Second, our blood vessels were evaluated in young, healthy pigs
instead of cardiovascular compromised individuals, using an end-
to-end interposition model. This model is frequently used to eval-
uate vascular grafts. Yet, in the clinical setting, end-to-end in-
terpositions are less commonly used. In future long-term studies,
the TEBV should be tested in a clinically more relevant setting. In
addition, these pigs are known to have a high re-endothelialization
capacity. Although the latter constrains direct extrapolation to the
human situation, it does imply that endothelial cells are able to
attach to the luminal surface of the tissue capsule.
Lastly, the question arises if the use of the external sheet is
necessary in view of the high burst pressure. Indeed, the burst
pressure of the tissue capsule before vascular grafting was suffi-
ciently high. However, burst pressure measurements are short term
measurement that do not account for tissue fatigue in the longer
term after vascular implantation. Therefore, we started using anexternal sheet that might be omitted if the tissue capsule demon-
strated to be fatigue proof after vascular grafting. Four weeks after
vascular grafting, the burst pressure of the tissue capsule remained
stable and was even non-significantly increased, likely due the
increase of circumferentially aligned collagen. Thus, the TEBV
seems to withstand the high arterial pressure. The application of an
external sheet may limit the usefulness of our approach. Therefore,
future experiments should be performed without the external
sheet.
5. Conclusion
In conclusion, using the subcutaneous space as in vivo biore-
actor, autologous tissue engineered blood vessels were rapidly
developed with sufficient mechanical strength to allow safe im-
plantation in the arterial circulation. Within 4 weeks, the TEBV
further remodeled and “arterialized” into an adequate vascular
conduit. Future experiments should reveal the long-term patency
of these TEBVs.
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